Roche Holding AG (RHHBY)
OTCMKTS
· Delayed Price · Currency is USD
34.50
+0.26 (0.76%)
Dec 20, 2024, 4:00 PM EST
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B CHF
Revenue Growth
-3.12%
P/S Ratio
n/a
Revenue / Employee
584.73K CHF
Employees
103,605
Market Cap
222.14B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Roche Holding AG News
- 2 days ago - Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits - Benzinga
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - WSJ
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - The Wall Street Journal
- 2 days ago - Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug - Seeking Alpha
- 3 days ago - Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus - GuruFocus
- 3 days ago - Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease - GlobeNewsWire
- 3 days ago - Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease - Business Wire
- 3 days ago - Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche - Investor's Business Daily